NXTC — NextCure, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1661059 ·
Last close
$7.02
Market Cap
$25.36M
52W High
$14.36
52W Low
$6.40
ADV30
58,054
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -10,105,000 | -9,796,000 | 37,977,000 | 15,167,000 | 11,261,000 |
| Dec 2025 | 0 | — | -9,757,000 | -9,436,000 | 50,183,000 | 25,982,000 | 15,240,000 |
| Sep 2025 | 0 | — | -8,945,000 | -8,624,000 | 39,613,000 | 7,324,000 | 15,967,000 |
| Jun 2025 | 0 | — | -27,292,000 | -26,808,000 | 47,689,000 | 4,892,000 | 16,043,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-49,613,000
Investing CF
$25,556,000
Financing CF
$22,312,000
CapEx
$-170,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-24.14
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-435,980,000
Inventory
—
Receivables
—
ST Investments
$15,836,000
EBIT TTM
$-57,616,000
Pretax Income TTM
$-55,844,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -57,616,000 | -55,844,000 | 50,183,000 | 15,240,000 | — | -49,613,000 |
| Dec 2024 | 0 | -57,206,000 | -55,654,000 | 80,860,000 | 15,388,000 | — | -40,805,000 |
| Dec 2023 | 0 | -67,637,000 | -62,723,000 | 128,038,000 | 13,617,000 | — | -52,974,000 |
| Dec 2022 | 0 | -75,909,000 | -74,733,000 | 184,161,000 | 16,631,000 | — | -53,886,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-8.35
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VTGN | Vistagen Therapeutics, Inc. | $25.23M | $0.64 | — |
| PTN | PALATIN TECHNOLOGIES INC | $25.70M | $14.44 | — |
| BCTX | BriaCell Therapeutics Corp. | $24.80M | $3.42 | — |
| CLRB | Cellectar Biosciences, Inc. | $24.77M | $3.10 | — |
| CELU | Celularity Inc | $25.96M | $0.90 | — |
News headlines (Yahoo Finance, 1h cache)
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-07 20:05 · Yahoo
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
2026-05-04 11:05 · Yahoo
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
2026-04-21 14:15 · Yahoo
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
2026-04-07 12:05 · Yahoo
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
2026-03-31 20:05 · Yahoo
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
2026-03-05 21:05 · Yahoo
NextCure Provides Business Update
2026-01-23 12:00 · Yahoo
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
2025-11-20 13:00 · Yahoo
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
2025-11-17 13:00 · Yahoo
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
2025-11-12 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.